Patient-Derived Melanoma Immune-Tumoroids for Drug Screening
Author Information
Author(s): Juliana Viegas, Sofia Costa, Sofia Dias, Catarina Leite Pereira, Bruno Sarmento
Primary Institution: i3S–Instituto de Investigação e Inovação em Saúde Universidade do Porto
Hypothesis
Can patient-derived melanoma immune-tumoroids serve as a reliable platform for high-throughput drug screening?
Conclusion
The study demonstrates that patient-derived melanoma immune-tumoroids closely mimic in vivo tumors and are effective for precision medicine drug screening.
Supporting Evidence
- The tumoroids replicated tumor architecture and behavior, closely resembling in vivo tumors.
- Drug screening showed that the tumoroids are effective platforms for precision medicine.
- The study highlights the importance of incorporating immune cells in tumor models.
Takeaway
Researchers created tiny tumor models from patient cells to test how well different cancer drugs work, helping to find better treatments.
Methodology
The study involved developing multicellular tumoroids from patient-derived cells and assessing their growth, metabolism, and response to various drugs.
Potential Biases
Potential bias in drug response due to the specific cell lines used.
Limitations
The study primarily focuses on melanoma and may not be generalizable to other cancer types.
Participant Demographics
Patient-derived cells from melanoma patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website